List of bibliographic references indexed by off
Number of relevant bibliographic references: 13.
| Ident. | Authors (with country if any) | Title |
|---|
| 000093 (2021) |
Derek Shyr [États-Unis] ; Yu Shyr [États-Unis] | The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic. |
| 000295 (2021) |
Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine] | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. |
| 000296 (2021) |
Victoria Birlutiu ; Rares Mircea Birlutiu ; Liana Chicea [Roumanie] | Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience. |
| 000611 (2021) |
Mary Kelly [Irlande (pays)] ; R Isìn O'Connor [Irlande (pays)] ; Liam Townsend [Irlande (pays)] ; Miriam Coghlan [Irlande (pays)] ; Eileen Relihan [Irlande (pays)] ; Miriam Moriarty [Irlande (pays)] ; Bernard Carr [Irlande (pays)] ; Gail Melanophy [Irlande (pays)] ; Caitriona Doyle [Irlande (pays)] ; Ciaran Bannan [Irlande (pays)] ; Ruth O'Riordan [Irlande (pays)] ; Concepta Merry [Irlande (pays)] ; Susie Clarke [Irlande (pays)] ; Colm Bergin [Irlande (pays)] | Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. |
| 000726 (2021) |
Annie Delaunois [Belgique] ; Matthew Abernathy [États-Unis] ; Warren D. Anderson [États-Unis] ; Kylie A. Beattie [Royaume-Uni] ; Khuram W. Chaudhary [États-Unis] ; Julie Coulot [Suisse] ; Vitalina Gryshkova [Belgique] ; Simon Hebeisen [Suisse] ; Mark Holbrook [Royaume-Uni] ; James Kramer [États-Unis] ; Yuri Kuryshev [États-Unis] ; Derek Leishman [États-Unis] ; Isabel Lushbough [Belgique] ; Elisa Passini [Royaume-Uni] ; Will S. Redfern [Royaume-Uni] ; Blanca Rodriguez [Royaume-Uni] ; Eric I. Rossman [États-Unis] ; Cristian Trovato [Royaume-Uni] ; Caiyun Wu [États-Unis] ; Jean-Pierre Valentin [Belgique] | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19. |
| 000885 (2020) |
Alexandre Gérard [France] ; Serena Romani [France] ; Audrey Fresse [France] ; Delphine Viard [France] ; Nadège Parassol [France] ; Aurélie Granvuillemin [France] ; Laurent Chouchana [France] ; Fanny Rocher [France] ; Milou-Daniel Drici [France] | "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. |
| 000F10 (2020) |
Allan Sauvat [France] ; Fabiola Ciccosanti [Italie] ; Francesca Colavita [Italie] ; Martina Di Rienzo [Italie] ; Concetta Castilletti [Italie] ; Maria Rosaria Capobianchi [Italie] ; Oliver Kepp [France] ; Laurence Zitvogel [France, République populaire de Chine] ; Gian Maria Fimia [Italie] ; Mauro Piacentini [Italie] ; Guido Kroemer [France, République populaire de Chine, Suède] | On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. |
| 000F12 (2020) |
J Simon Bell ; John A. Bell ; Darren J. Creek | Off-label prescribing in the midst of a pandemic: The case of hydroxychloroquine. |
| 000F13 (2020) |
Anteneh Belayneh [Éthiopie] | Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation. |
| 000F14 (2020) |
Jonathan D. Alpern [États-Unis] ; Elie Gertner [États-Unis] | Off-Label Therapies for COVID-19-Are We All In This Together? |
| 000F15 (2020) |
Francisco José Roma Paumgartten [Brésil] ; Ana Cecilia Amado Xavier De Oliveira [Brésil] | Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. |
| 001631 (2020) |
Pascale M. Abena [Cameroun] ; Eric H. Decloedt [Afrique du Sud] ; Emmanuel Bottieau [Belgique] ; Fatima Suleman [Afrique du Sud] ; Prisca Adejumo [Nigeria] ; Nadia A. Sam-Agudu [Ghana, Nigeria, États-Unis] ; Jean-Jacques Muyembe Tamfum ; Moussa Seydi [Sénégal] ; Serge P. Eholie [Côte d'Ivoire] ; Edward J. Mills [Rwanda] ; Oscar Kallay [Belgique] ; Alimuddin Zumla [Royaume-Uni] ; Jean B. Nachega [Afrique du Sud, États-Unis] | Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. |
| 001682 (2020) |
Niyada Naksuk [États-Unis] ; Sorin Lazar [États-Unis] ; Thoetchai Bee Peeraphatdit [États-Unis] | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "off"
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i \
-Sk "off" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= indexItem
|index= Title.i
|clé= off
}}
| This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021 |  |
